Metabolism

Natural Peptide Protects Retinal Cells in Laboratory Diabetes Model

Researchers found that the Ac2-26 peptide preserved retinal neurons exposed to high glucose in stem cell models.

Published November 20, 2026 Read 3 min 467 words Topic Metabolism
Reviewed by: Dr. Michael Teplitsky, MD · November 2026

Laboratory Study Identifies Peptide Protective Against Glucose Damage

A naturally occurring peptide called Ac2-26 protected retinal neurons from damage caused by elevated glucose in laboratory models. The study appeared in the journal Biomedicine & Pharmacotherapy and evaluated tissue models developed from human stem cells.

Researchers from the Federal University of São Paulo (UNIFESP) and São Paulo State University (UNESP) in Brazil collaborated with scientists at the University of Colorado Anschutz on the project. Their experiments tested how the peptide affected isolated retinal cell cultures and three-dimensional retinal organoids.

Diabetic retinopathy affects more than 22 percent of individuals with diabetes globally. The condition develops when persistent high blood sugar triggers retinal inflammation and damages both blood vessels and nerve cells.

Peptide Targets Early Cellular Stress and Neuronal Loss

The Ac2-26 peptide preserved retinal neurons by reducing inflammation, curbing oxidative stress, and maintaining mitochondrial function. Mitochondria generate cellular energy, and glucose-induced stress typically disrupts their normal activity in retinal tissue.

By preserving mitochondrial activity, the compound prevented cell death pathways from activating in neurons exposed to high glucose. Rafael André da Silva, first author of the study at the University of Colorado Anschutz, noted that current clinical treatments target the later neovascularization phase where abnormal blood vessels grow.

Retinal neurons do not regenerate after they die. Protecting these cells during the earliest stages of metabolic stress addresses damage that existing vascular therapies cannot reverse.

Retinopathy Involves Early Neural Tissue Damage

Diabetic retinopathy begins damaging neural tissue before abnormal blood vessels appear in the eye. Natalia Vergara, director of the Laboratory of Ocular Development and Translational Technologies at CellSight at the University of Colorado Anschutz, explained that the condition is not solely a vascular disorder.

As high glucose persists, oxidative stress causes premature death among retinal neurons. The eye then attempts to compensate by forming fragile new blood vessels through angiogenesis, which leak fluid and cause hemorrhages that worsen vision loss.

The Ac2-26 peptide is derived from Annexin A1, an anti-inflammatory protein that regulates retinal blood vessels and supportive glial cells. Testing the molecule in human organoids confirmed that targeting these pathways directly shields neurons from toxic glucose exposure.

Current Evidence Remains Limited to Preclinical Models

The findings come entirely from in vitro cell cultures and stem cell-derived retinal organoids rather than human clinical trials. While organoids mimic human retinal architecture, they cannot replicate whole-body metabolic interactions, blood flow, or long-term systemic drug delivery.

The Ac2-26 peptide is not an approved medication, and researchers have not yet established dosing schedules or safety profiles in living eyes. Patients managing diabetic retinopathy must rely on approved treatments, regular dilated eye exams, and blood glucose management guided by their healthcare providers.

Future research must evaluate whether synthetic versions of the peptide can reach the retina safely in animal models before human testing begins.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.
Primary source: View original source — referenced for fact-checking; this analysis is independent editorial content.
Found this useful?

Related Articles

Want peptides prescribed and monitored properly?

If you're considering peptide therapy, the difference between a clinical program and a gray-market vial is supervision. Opt Health prescribes peptides through licensed physicians with baseline labs and follow-up testing.

See Opt Health's peptide program →

Topic updates

Get the weekly metabolic health roundup

Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.

No spam. Unsubscribe anytime.

Understand Your Health Better

Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results